<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0211234423
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NIVESTIM 600 mcg Solution for Injection/ Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FILGRASTIM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        315.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA ZAGREB D.O.O." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA ZAGREB D.O.O.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nivestim is a white blood cell growth factor (granulocyte-colony-stimulating factor) and belongs to a group of medicines called cytokines. Growth factors are proteins that are produced naturally in the body but they can also be made using biotechnology for use as a medicine. Nivestim works by encouraging the bone marrow to produce more white blood cells.</p><p>&nbsp;</p><p>A reduction in the number of white blood cells (neutropenia) can occur for several reasons and makes your body less able to fight infection. Nivestim stimulates the bone marrow to produce new white cells quickly.</p><p>&nbsp;</p><p>Nivestim can be used:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells after treatment with chemotherapy to help prevent infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells after a bone marrow transplant to help prevent infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; before high-dose chemotherapy to make the bone marrow produce more stem cells which can be collected and given back to you after your treatment. These can be taken from you or from a donor. The stem cells will then go back into the bone marrow and produce blood cells;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to increase the number of white blood cells if you suffer from severe chronic neutropenia to help prevent infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with advanced HIV infection which will help reduce the risk of infections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Nivestim</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to filgrastim or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Nivestim.</p><p>&nbsp;</p><p>Please tell your doctor before starting treatment <strong>if you have</strong>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sickle cell anaemia, as Nivestim may cause sickle cell crisis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoporosis (bone disease).</p><p>&nbsp;</p><p>Please tell your doctor immediately during treatment with Nivestim, if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have sudden signs of allergy such as rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing as these could be signs of a severe allergic reaction (hypersensitivity).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual (glomerulonephritis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get left upper belly (abdominal) pain, pain below the left rib cage or at the tip of your left shoulder (these may be symptoms of an enlarged spleen (splenomegaly), or possibly rupture of the spleen).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; notice unusual bleeding or bruising (these may be symptoms of a decrease in blood platelets (thrombocytopenia), with a reduced ability of your blood to clot).</p><p>&nbsp;</p><p>Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported rarely in cancer patients and healthy donors. The symptoms can include fever, abdominal pain, malaise, back pain and increased inflammatory markers. Tell your doctor if you experience these symptoms.</p><p>&nbsp;</p><p><strong>Loss of response to filgrastim</strong></p><p><strong>&nbsp;</strong></p><p>If you experience a loss of response or failure to maintain a response with filgrastim treatment, your doctor will investigate the reasons why including whether you have developed antibodies which neutralise filgrastim&rsquo;s activity.</p><p>&nbsp;</p><p>Your doctor may want to monitor you closely, see section 4 of the package leaflet.</p><p>&nbsp;</p><p>If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome (MDS)). You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop cancers of the blood, you should not use Nivestim, unless instructed by your doctor.</p><p>&nbsp;</p><p>If you are a stem cell donor, you must be aged between 16 and 60 years.</p><p>&nbsp;</p><p><strong>Take special care with other products that stimulate white blood cells</strong></p><p>&nbsp;</p><p>Nivestim is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.</p><p>&nbsp;</p><p><strong>Other medicines and Nivestim</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>Nivestim has not been tested in pregnant or breast-feeding women.</p><p>&nbsp;</p><p>Nivestim is not recommended during pregnancy.</p><p>&nbsp;</p><p>It is important to tell your doctor if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or breast-feeding;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; think you may be pregnant; or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are planning to have a baby.</p><p>&nbsp;</p><p>If you become pregnant during Nivestim treatment, please inform your doctor.</p><p>&nbsp;</p><p>Unless your doctor directs you otherwise, you must stop breast‑feeding if you use Nivestim.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Nivestim may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after taking Nivestim and before driving or operating machinery.</p><p>&nbsp;</p><p><strong>Nivestim contains sodium </strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 0.6&nbsp;mg/ml or 0.96&nbsp;mg/ml dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p><p><strong>Nivestim contains sorbitol</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains 50 mg sorbitol in each ml.</p><p>&nbsp;</p><p>Sorbitol is a source of fructose. If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose, which may cause serious side effects.</p><p>&nbsp;</p><p>You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How is Nivestim given and how much should I take?</strong></p><p>&nbsp;</p><p>Nivestim is usually given as a daily injection into the tissue just under the skin (known as a subcutaneous injection). It can also be given as a daily slow injection into the vein (known as an intravenous infusion). The usual dose varies depending on your illness and weight. Your doctor will tell you how much Nivestim you should take.</p><p>&nbsp;</p><p>Patients having a bone marrow transplant after chemotherapy:</p><p>You will normally receive your first dose of Nivestim at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant.</p><p>&nbsp;</p><p>You, or people caring for you, can be taught how to give subcutaneous injections so that you can continue your treatment at home. However, you should not attempt this unless you have been properly trained first by your healthcare provider.</p><p>&nbsp;</p><p><strong>How long will I have to take Nivestim?</strong></p><p>&nbsp;</p><p>You will need to take Nivestim until your white blood cell count is normal. Regular blood tests will be taken to monitor the number of white blood cells in your body. Your doctor will tell you how long you will need to take Nivestim.</p><p>&nbsp;</p><p><strong>Use in children</strong></p><p>&nbsp;</p><p>Nivestim is used to treat children who are receiving chemotherapy or who suffer from severe low white blood cell count (neutropenia). The dosing in children receiving chemotherapy is the same as for adults.</p><p>&nbsp;</p><p><strong>If you use more Nivestim than you should</strong></p><p><strong>&nbsp;</strong></p><p>Do not increase the dose your doctor has given you. If you think you have injected more than you should, contact your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>If you forget to use Nivestim</strong></p><p>&nbsp;</p><p>If you have missed an injection, or injected too little, contact your doctor as soon as possible. Do not take a double dose to make up for any missed doses.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Please tell your doctor immediately </strong>during treatment:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience an allergic reaction including weakness, drop in blood pressure, difficulty breathing, swelling of the face (anaphylaxis), skin rash, itchy rash (urticaria), swelling of the face, lips, mouth, tongue or throat (angioedema) and shortness of breath (dyspnoea).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a cough, fever and difficulty breathing (dyspnoea) as this can be a sign of Acute Respiratory Distress Syndrome (ARDS).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience kidney injury (glomerulonephritis). Kidney injury has been seen in patients who received filgrastim. Call your doctor right away if you experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any of the following or combination of the following side effects:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or puffiness, which may be associated with passing water less frequently, difficulty breathing, abdominal swelling and feeling of fullness, and a general feeling of tiredness. These symptoms generally develop in a rapid fashion.</p><p>These could be symptoms of a condition called &ldquo;Capillary Leak Syndrome&rdquo; which causes blood to leak from the small blood vessels into your body and needs urgent medical attention.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a combination of any of the following symptoms:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, or shivering, or feeling very cold, high heart rate, confusion or disorientation, shortness of breath, extreme pain or discomfort and clammy or sweaty skin.</p><p>These could be symptoms of a condition called &ldquo;sepsis&rdquo; (also called &ldquo;blood poisoning&rdquo;), a severe infection with whole-body inflammatory response which can be life threatening and needs urgent medical attention.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get left upper belly (abdominal) pain, pain below the left rib cage or pain at the tip of your shoulder, as there may be a problem with your spleen (enlargement of the spleen (splenomegaly) or rupture of the spleen).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated for severe chronic neutropenia and you have blood in your urine (haematuria). Your doctor may regularly test your urine if you experience this side effect or if protein is found in your urine (proteinuria).</p><p>&nbsp;</p><p>A common side effect of filgrastim use is pain in your muscles or bones (musculoskeletal pain), which can be helped by taking standard pain relief medicines (analgesics). In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur - this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.</p><p>&nbsp;</p><p>In normal stem cell donors, an increase in white blood cells (leucocytosis) and a decrease of platelets may be seen. This reduces the ability of your blood to clot (thrombocytopenia). These will be monitored by your doctor.</p><p>&nbsp;</p><p><strong>Very common side effects</strong> (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of platelets which reduces the ability of blood to clot (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell count (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair loss or thinning (alopecia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; soreness and swelling of the digestive tract lining which runs from the mouth to the anus (mucosal inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lung (bronchitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased feeling of sensitivity, especially in the skin (hypoaesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness of the hands or feet (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood (haemoptysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your mouth and throat (oropharyngeal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds (epistaxis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlargement of the liver (hepatomegaly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin (erythema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine (dysuria)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generalised weakness (asthenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the hands and feet (oedema peripheral)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of certain enzymes in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood chemistry</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transfusion reaction</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in white blood cells (leucocytosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (hypersensitivity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rejection of transplanted bone marrow (graft versus host disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high uric acid levels in the blood, which may cause gout (hyperuricaemia) (Blood uric acid increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver damage caused by blocking of the small veins within the liver (veno-occlusive disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lungs do not function as they should, causing breathlessness (respiratory failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling and/or fluid in the lungs (pulmonary oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs (interstitial lung disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal x-rays of the lungs (lung infiltration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the lung (pulmonary haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of absorption of oxygen in the lung (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bumpy skin rash (rash maculo-papular)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease which causes bones to become less dense, making them weaker, more brittle and likely to break (osteoporosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe pain in the bones, chest, gut or joints (sickle cell anaemia with crisis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden life-threatening allergic reaction (anaphylactic reaction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain and swelling of the joints, similar to gout (pseudogout)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in how your body regulates fluids within your body and may result in puffiness (fluid volume disturbances)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the blood vessels in the skin (cutaneous vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever (Sweets syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of rheumatoid arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual change in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone density decreased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the aorta (the large blood vessel which transports blood from the heart to the body), see section 2</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>TO REPORT ANY SIDE EFFECTS:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;</strong><strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life: 30 months.</p><p>&nbsp;</p><p>Store and transport refrigerated (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 15 days (but not above 25&deg;C).</p><p>After dilution use within 24 hours</p><p>&nbsp;</p><p>Accidental exposure to freezing temperatures for up to 24 hours does not affect the stability of Nivestim. The frozen pre-filled syringes can be thawed and then refrigerated for future use. If exposure has been greater than 24 hours or frozen more than once, then Nivestim should NOT be used.</p><p>&nbsp;</p><p>Do not use this medicine if you notice it is cloudy or there are particles in it.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is filgrastim. Each ml contains 60&nbsp;million units [MU] (600 mcg) or 96&nbsp;million units [MU] (960&nbsp;mcg) of filgrastim.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nivestim 12&nbsp;MU/0.2&nbsp;ml solution for injection/infusion: each pre-filled syringe contains 12&nbsp;million units (MU), 120&nbsp;mcg of filgrastim in 0.2 ml (corresponding to 0.6&nbsp;mg/ml).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nivestim 30&nbsp;MU/0.5&nbsp;ml solution for injection/infusion: each pre-filled syringe contains 30&nbsp;million units (MU), 300&nbsp;mcg of filgrastim in 0.5 ml&nbsp;(corresponding to 0.6&nbsp;mg/ml).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nivestim 48&nbsp;MU/0.5&nbsp;ml solution for injection/infusion: each pre-filled syringe contains 48&nbsp;million units (MU), 480&nbsp;mcg of filgrastim in 0.5&nbsp;ml (corresponding to 0.96&nbsp;mg/ml).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are acetic acid (glacial), sodium hydroxide, sorbitol E420, polysorbate 80, and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nivestim is a clear colourless solution for injection/infusion in a glass pre-filled syringe with an injection needle (stainless steel) with a needle guard. The needle cover contains epoxyprene, a derivative of natural rubber latex which may come into contact with the needle. 
There are 1, 5, 8 or 10 syringes in each pack. Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Europe MA EEIG, Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hospira Zagreb d.o.o., Croatia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">نيفيستيم هو أحد عوامل نمو خلايا الدم البيضاء (عامل تحفيز مستعمرات الخلايا المحببة)، وهو ينتمي إلى مجموعة من الأدوية تُسمى السيتوكينات. عوامل النمو هي بروتينات تُنتج في الجسم بصورة طبيعية، ولكن يمكن تصنيعها أيضًا باستخدام التقنية الحيوية لاستخدامها كدواء. يعمل نيفيستيم من خلال حث نخاع العظم على إنتاج المزيد من خلايا الدم البيضاء.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يحدث انخفاض في عدد خلايا الدم البيضاء (قلة العدلات) نتيجةً لأسباب عديدة، وهذا الانخفاض يقلل من قدرة جسمك على محاربة العدوى. يحفز نيفيستيم نخاع العظم لإنتاج خلايا دم بيضاء جديدة بسرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام نيفيستيم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لزيادة عدد خلايا الدم البيضاء بعد الخضوع للعلاج الكيميائي للمساعدة في منع حالات العدوى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لزيادة عدد خلايا الدم البيضاء بعد عملية زراعة نخاع العظم للمساعدة في منع حالات العدوى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تلقّي جرعة عالية من العلاج الكيميائي لتحفيز نخاع العظم على إنتاج عدد أكبر من الخلايا الجذعية التي يمكن جمعها وإعطاؤها لك مرة أخرى بعد خضوعك للعلاج. يمكن أن تؤخذ هذه الخلايا منك أو من أحد المتبرعين. وبعد ذلك ستعود الخلايا الجذعية إلى نخاع العظم وستنتج خلايا دم؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لزيادة عدد خلايا الدم البيضاء إذا كنت تعاني من حالة شديدة مزمنة من قلة العدلات، وذلك للمساعدة في منع حالات العدوى؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مع المرضى المصابين بحالة متقدمة من عدوى فيروس نقص المناعة البشرية (HIV) مما سيساعد في تقليل خطر الإصابة بالعدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال نيفيستيم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه فيلجراستيم أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال نيفيستيم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام نيفيستيم.</p><p>&nbsp;</p><p dir="RTL">يرجى إخبار طبيبك قبل بدء العلاج <strong>إذا كنت مصابًا بما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم المنجلي، نظرًا لأن نيفيستيم قد يتسبب في حدوث أزمة الخلايا المنجلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هشاشة العظام (مرض بالعظام).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إخبار طبيبك فورًا أثناء العلاج بنيفيستيم، إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبت بعلامات مفاجئة على الحساسية مثل ظهور الطفح الجلدي أو الحكة أو الشرى على الجلد، أو تورم الوجه، أو الشفتين، أو اللسان أو أجزاء أخرى في الجسم، أو ضيق التنفس، أو الأزيز، أو صعوبة في التنفس حيث إن هذه قد تكون علامات تفاعل حساسية شديد (فرط الحساسية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أصبت بانتفاخ في وجهك أو كاحليك، أو في حالة وجود دم في بولك، أو تغيّر لون البول إلى البني أو إذا لاحظت أنك تتبول بمعدل أقل من المعتاد (التهاب كبيبات الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعرت بألم في الجزء العلوي الأيسر من البطن، أو بألم أسفل الجهة اليسرى للقفص الصدري أو عند طرف كتفك الأيسر (قد تكون هذه أعراض الإصابة بتضخم الطحال أو تمزق محتمل في الطحال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاحظت نزيفًا أو تكدمًا غير معتاد (قد تكون هذه أعراض انخفاض عدد الصفيحات الدموية (قلة الصفيحات)، مع انخفاض قدرة دمك على التجلط).</p><p>&nbsp;</p><p dir="RTL">لقد تم الإبلاغ عن حالات نادرة من التهاب الشريان الأبهر (الوعاء الدموي الكبير الذي ينقل الدم من القلب إلى الجسم) لدى المرضى المصابين بالسرطان والمتبرعين الأصحاء. يمكن أن تتضمن الأعراض الحمى، وألم البطن، والتوعك، وألم الظهر، وزيادة نسبة المؤشرات الالتهابية. أخبر طبيبك إذا أصبت بهذه الأعراض.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;فقدان الاستجابة لفيلجراستيم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا فقدت استجابتك أو لم تحافظ على درجة استجابتك للعلاج بفيلجراستيم، فسيبحث طبيبك في أسباب هذا الأمر، بما في ذلك إذا ما كانت قد تطورت لديك أجسام مضادة تقوم بمعادلة تأثير فيلجراستيم أم لا.</p><p>&nbsp;</p><p dir="RTL">قد يرغب طبيبك في مراقبة حالتك عن كثب، انظر القسم ٤ من النشرة الداخلية.</p><p>&nbsp;</p><p dir="RTL">إذا كنت مريضًا مصابًا بحالة شديدة مزمنة من قلة العدلات، فقد تكون عرضة لخطر الإصابة بسرطان الدم (ابيضاض الدم، متلازمة خلل التنسج النقوي (MDS)). ينبغي أن تتحدث إلى طبيبك حول مخاطر تعرضك للإصابة بسرطانات الدم وما هي الاختبارات التي ينبغي إجراؤها. إذا أصبت أو كان من المحتمل أن تصاب بسرطانات الدم، ينبغي ألا تستخدم نيفيستيم، إلا إذا كان ذلك بتوجيهات من طبيبك.</p><p>&nbsp;</p><p dir="RTL">إذا كنت متبرعًا بالخلايا الجذعية، يجب أن يكون عمرك بين ١٦ و٦٠ عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخ الحذر بشكل خاص مع المنتجات الأخرى التي تحفّز خلايا الدم البيضاء</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">نيفيستيم هو واحد من مجموعة من المنتجات التي تحفّز إنتاج خلايا الدم البيضاء. ينبغي أن يقوم أخصائي الرعاية الصحية الخاص بك دائمًا بتسجيل المنتج المحدد الذي تستخدمه.</p><p>&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لم يُختبر استخدام نيفيستيم مع السيدات الحوامل أو اللاتي يُرضعن رضاعة طبيعية.</p><p>&nbsp;</p><p dir="RTL">لا يوصى باستخدام نيفيستيم أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;من المهم أن تخبري طبيبكِ إذا كنتِ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملًا أو ترضعين رضاعة طبيعية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو تعتقدين أنكِ ربما تكونين حاملًا؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أو تخططين للإنجاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا أصبحتِ حاملًا أثناء العلاج بنيفيستيم، يُرجى إبلاغ طبيبكِ.</p><p>&nbsp;</p><p dir="RTL">يجب عليكِ إيقاف الرضاعة الطبيعية إذا كنتِ تستخدمين نيفيستيم، ما لم يوجهكِ طبيبكِ إلى خلاف ذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير نيفيستيم على القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يكون لنيفيستيم تأثير طفيف على قدرتك على القيادة واستخدام الآلات. فقد يسبب هذا الدواء الإصابة بالدوار. لذا يُنصح بالانتظار لمعرفة شعورك بعد تناول نيفيستيم وقبل القيادة أو تشغيل الآلات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات نيفيستيم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي نيفيستيم على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول من الصوديوم (٢٣ ملجم) لكل جرعة مقدارها ٠.٦ ملجم/مل أو ٠.٩٦ ملجم/مل، ولذلك يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي نيفيستيم على السوربيتول</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على ٥٠ ملجم من السوربيتول لكل مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">السوربيتول هو مصدر للفركتوز. إذا كنت (أو كان طفلك) مصابًا بعدم تحمل الفركتوز الوراثي (HFI)، وهو اضطراب جيني نادر،&nbsp; يجب ألا تتلقى (أو يتلقى طفلك) هذا الدواء. فالمرضى المصابون بعدم تحمل الفركتوز الوراثي لا يستطيعون تحليل الفركتوز، وهو ما قد يؤدي إلى آثار جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تخبر طبيبك قبل تلقي هذا الدواء إذا كنت (أو كان طفلك) مصابًا بعدم تحمل الفركتوز الوراثي أو إذا لم يعد بإمكان طفلك أن يتناول الأطعمة أو المشروبات السكرية بسبب إصابته بالغثيان أو القيء أو إصابته بآثار مزعجة مثل الانتفاخ أو تقلصات في المعدة أو الإسهال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على استخدام هذا الدواء كما أخبرك طبيبك تمامًا. راجع طبيبك أو الممرضة أو الصيدلي إذا لم تكن متأكدًا مما ينبغي عليك فعله.</p><p>&nbsp;</p><p dir="RTL"><strong>كيف يتم إعطاء نيفيستيم وما هي الكمية التي ينبغي أن أتناولها؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">عادةً ما يتم إعطاء نيفيستيم في صورة حقن في الأنسجة تحت الجلد مباشرة يوميًا (يُعرف باسم الحقن تحت الجلد). ويمكن إعطاؤه أيضًا في صورة حقن بطيء في الوريد يوميًا (يُعرف باسم التسريب عبر الوريد). تتفاوت الجرعة المعتادة بناءً على المرض الذي تعاني منه ووزنك. سيخبرك طبيبك بالجرعة التي ينبغي أن تتناولها من نيفيستيم.</p><p>&nbsp;</p><p dir="RTL">المرضى الذين سيخضعون لعملية زراعة نخاع العظم بعد العلاج الكيميائي:</p><p dir="RTL">في المعتاد، سوف تتلقى جرعتك الأولى من نيفيستيم بعد ٢٤ ساعة على الأقل من خضوعك للعلاج الكيميائي وبعد ٢٤ ساعة على الأقل من خضوعك لعملية زراعة نخاع العظم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تعليمك، أو تعليم الأشخاص القائمين على رعايتك، كيفية إعطاء الحقن تحت الجلد لكي تتمكن من إكمال علاجك في المنزل. ولكن، ينبغي ألا تحاول فعل ذلك إلا بعد أن يتم تدريبك بشكل ملائم أولًا بواسطة مقدم الرعاية الصحية الخاص بك.</p><p>&nbsp;</p><p dir="RTL"><strong>ما هي المدة التي ينبغي أن أتناول نيفيستيم خلالها؟</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيتعين عليك تناول نيفيستيم إلى أن يصبح تعداد خلايا دمك البيضاء طبيعيًا. سيتم إجراء فحوصات دم منتظمة لمراقبة عدد خلايا الدم البيضاء في جسمك. سيخبرك طبيبك بالمدة التي ينبغي عليك تناول نيفيستيم خلالها.</p><p>&nbsp;</p><p dir="RTL"><strong>الاستخدام مع الأطفال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يُستخدم نيفيستيم لعلاج الأطفال الذين يتلقون علاجًا كيميائيًا أو الذين يعانون من انخفاض شديد في تعداد خلايا الدم البيضاء (قلة العدلات). إن الجرعات المعطاة للأطفال الذين يتلقون علاجًا كيميائيًا هي نفس جرعات البالغين.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من نيفيستيم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بزيادة الجرعة التي أعطاها لك طبيبك. إذا كنت تعتقد أنك قد حقنت جرعة أكبر مما ينبغي، فتواصل مع طبيبك في أسرع وقت ممكن.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة نيفيستيم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا فوتّ إحدى الحقن، أو حقنت جرعة صغيرة للغاية، فتواصل مع طبيبك في أسرع وقت ممكن. لا تأخذ جرعة مضاعفة لتعويض أي جرعات فائتة.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاسأل طبيبك أو الممرضة أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL">أثناء العلاج، <strong>يرجى إخبار طبيبك على الفور:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتفاعل حساسية بما في ذلك الضعف، وانخفاض ضغط الدم، وصعوبة التنفس، وتورم الوجه (التأق)، والطفح الجلدي، والطفح الجلدي المثير للحكة (ارتيكاريا)، وتورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق (تورم وعائي)، وضيق التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بالسعال والحمى وصعوبة التنفس (ضيق التنفس)، حيث قد يكون هذا علامة على الإصابة بمتلازمة الضائقة التنفسية الحادة (ARDS).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بمشكلة في الكلى (التهاب كبيبات الكلى). تمت ملاحظة إصابة الكلى في المرضى الذين تلقوا فيلجراستيم. اتصل بطبيبك على الفور إذا أصبت بانتفاخ في وجهك أو كاحليك، أو عند ظهور دم في بولك، أو تغيّر لون البول إلى البني، أو إذا لاحظت أنك تتبول بمعدل أقل من المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأي من الآثار الجانبية التالية أو بمجموعة منها:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو انتفاخ، وهو ما قد يكون مرتبطًا بالتبول بمعدل أقل، وصعوبة التنفس، وتورم البطن وشعور بالامتلاء، وشعور عام بالتعب. تحدث هذه الأعراض عامة بصورة سريعة.</p><p dir="RTL">يمكن أن تكون هذه أعراض لحالة تسمى &quot;متلازمة التسرب الشعيري&quot; التي تسبب تسرب الدم من الأوعية الدموية الصغيرة إلى جسمك وتستلزم عناية طبية عاجلة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بمجموعة من أي من الأعراض التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى أو الارتعاش أو الشعور بالبرد الشديد، وارتفاع معدل ضربات القلب أو الارتباك أو التشتت، وضيق التنفس أو الألم أو الانزعاج الشديدين، ورطوبة أو تعرق الجلد.</p><p dir="RTL">يمكن أن تكون هذه أعراضًا لحالة تسمى &quot;الإنتان&quot; (تسمى أيضًا &quot;تسمم الدم&quot;)، وهي عدوى شديدة مصحوبة بتفاعل التهابي في الجسم كله يمكن أن تكون مهددة للحياة وتستدعي الرعاية الطبية العاجلة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بألم في الجزء العلوي الأيسر من البطن أو ألم أسفل الجهة اليسرى للقفص الصدري أو ألم في طرف كتفك، حيث قد تكون هناك مشكلة في الطحال لديك (تضخم الطحال أو تمزق الطحال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان يتم علاجك من قلة العدلات الشديدة المزمنة ويوجد دم في البول لديك (البول الدموي). سوف يقوم طبيبك بفحص بولك بانتظام إذا أصبت بهذا الأثر الجانبي أو إذا تم العثور على بروتين في بولك (بيلة بروتينية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحد الآثار الجانبية الشائعة عند استخدام فيلجراستيم هو الإصابة بألم في العضلات أو العظام (ألم عضلي هيكلي)،</p><p dir="RTL">الذي يمكن تخفيفه بتناول الأدوية المسكنة للألم المعتادة (المسكنات). في المرضى الذين يخضعون</p><p dir="RTL">لزراعة الخلايا الجذعية أو نخاع العظم، قد يحدث مرض الطعم ضد المضيف (GvHD)، وهو تفاعل لخلايا المتبرع تجاه المريض الذي خضع لعملية الزرع؛ وتتضمن العلامات والأعراض طفح جلدي على راحتي يديك أو باطن قدميك وقرح وتقرحات في الفم أو الأمعاء أو الكبد أو الجلد أو العينين والرئتين والمهبل والمفاصل لديك.</p><p dir="RTL">&nbsp;لدى متبرعي الخلايا الجذعية الطبيعيين، يمكن ملاحظة زيادة خلايا الدم البيضاء (كثرة الكريات البيضاء) وانخفاض في عدد الصفيحات الدموية. وهذا يقلل من قدرة دمك على التجلط (قلة الصفيحات). سيقوم طبيبك بمراقبة هذه الأمور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص):</p><ul><li dir="RTL">نقص الصفيحات الدموية الذي يخفض من قدرة الدم على التجلط (قلة الصفيحات)</li><li dir="RTL">انخفاض في تعداد خلايا الدم الحمراء (فقر الدم)</li><li dir="RTL">الصداع</li><li dir="RTL">الإسهال</li><li dir="RTL">القيء</li><li dir="RTL">الغثيان</li><li dir="RTL">سقوط الشعر أو خفته بشكل غير معتاد (الثعلبة)التعب (الإرهاق)</li><li dir="RTL">تقرح وتورم بطانة القناة الهضمية التي تمتد من الفم إلى الشرج (التهاب الأغشية المخاطية)</li><li dir="RTL">الحمى (السخونة)</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين (الالتهاب الشعبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><ul><li dir="RTL">انخفاض الشهية</li></ul><ul><li dir="RTL">صعوبة في النوم (الأرق)</li><li dir="RTL">دوار</li><li dir="RTL">انخفاض الشعور بالحساسية، خاصة في الجلد (نقص الحس)</li><li dir="RTL">التنميل أو الخدر في اليدين أو القدمين (المذل)</li><li dir="RTL">ضغط الدم المنخفض (انخفاض ضغط الدم)</li><li dir="RTL">ضغط الدم المرتفع (ارتفاع ضغط الدم)</li><li dir="RTL">السعال</li><li dir="RTL">سعال دموي (بصق الدم)</li><li dir="RTL">ألم في الفم والحلق (ألم الفم والبلعوم)</li><li dir="RTL">نزيف الأنف (الرعاف)</li><li dir="RTL">الإمساك</li><li dir="RTL">ألم في الفم</li><li dir="RTL">تضخم الكبد</li><li dir="RTL">الطفح</li><li dir="RTL">احمرار الجلد (بقع حمراء)</li><li dir="RTL">تشنج العضلات</li><li dir="RTL">ألم عند التبول (عسر التبول)</li><li dir="RTL">ألم الصدر</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم</p><ul><li dir="RTL">الضعف المعمم (الوهن)</li><li dir="RTL">الشعور العام بالتوعك</li><li dir="RTL">تورم اليدين والقدمين (تورم محيطي)</li><li dir="RTL">زيادة إنزيمات معينة في الدم</li><li dir="RTL">تغيرات في كيمياء الدم</li><li dir="RTL">تفاعل تجاه نقل الدم</li></ul><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خلايا الدم البيضاء (كثرة الكريات البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية (فرط الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رفض نخاع العظم المزروع (مرض الطعم ضد المضيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات حمض اليوريك في الدم، الذي قد يسبب الإصابة بالنقرس (فرط يوريا الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضرر الكبد بسبب انسداد أوردة صغيرة في الكبد (مرض الانسداد الوريدي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم عمل الرئتين كما ينبغي، مما يسبب صعوبة التنفس (فشل تنفسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم و/أو وجود سوائل في الرئتين (تورم رئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين (المرض الرئوي الخلالي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية للفحص بالأشعة السينية على الرئتين (ارتشاح الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئة (النزف الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص امتصاص الأكسجين في الرئة (نقص التأكسج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي في صورة نتوءات (طفح بقعي حطاطي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض يسبب نقص كثافة العظام، مما يجعلها أضعف وأرق وسهلة الانكسار (هشاشة العظام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل في موضع الحقن</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في العظام، أو الصدر، أو الأمعاء، أو المفاصل (أنيميا الخلايا المنجلية المصحوبة بأزمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية مفاجئ مهدد للحياة (تفاعل تأقي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم المفاصل، مشابه للنقرس (النقرس الكاذب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في طريقة توزيع جسمك للسوائل داخل جسمك وقد ينتج عنه انتفاخ (اضطرابات في حجم السوائل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في الجلد (التهاب الأوعية الدموية الجلدية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات مؤلمة وبارزة أرجوانية اللون على الأطراف وفي بعض الأحيان على الوجه والرقبة تصحبها حمى (متلازمة سويت)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم حالة التهاب المفاصل الروماتويدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير غير معتاد في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كثافة العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأبهر (الوعاء الدموي الكبير الذي ينقل الدم من القلب إلى الجسم)، انظر القسم ٢</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><br />إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong>:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائية</p><ul><li dir="RTL">الرقم المجاني: ١٩٩٩٩</li><li dir="RTL">&nbsp;البريد الإلكتروني:<em> </em>npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني:<em><u> </u></em>https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ الصلاحية المدون على العبوة الكرتونية الخارجية وعلى المحقنة مسبقة التعبئة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">قم بتخزينه ونقله مبردًا (من ٢ إلى ٨ درجات مئوية). لا تقم بتجميده. احفظ المحقنة مسبقة التعبئة في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إزالة المحقنة من البراد (الثلاجة)<strong> </strong>وتركها في درجة حرارة الغرفة لفترة واحدة بحد أقصى ٧١٥ أيام <strong>)</strong>ولكن ليس في درجة حرارة أكثر من <strong>&nbsp;</strong>&nbsp;<strong>٢٥</strong><strong> </strong>&nbsp;درجة مئوية)<strong>.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">لا يؤثر التعرض العرضي لدرجات حرارة التجمد لمدة تصل إلى ٢٤ ساعة على ثبات نيفيستيم. يُمكن إذابة المحاقن مسبقة التعبئة المجمدة وحفظها في الثلاجة للاستخدام في المستقبل. إذا زادت مدة التعرض عن ٢٤ ساعة أو تم تجميده أكثر من مرة، فحينئذ ينبغي عدم استخدام نيفيستيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذ الدواء إذا لاحظت أنه عكر أو يحتوي على جسيمات.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي فيلجراستيم. يحتوي كل مل على ٦٠ مليون وحدة <strong>[MU]</strong> (٦٠٠ ميكروجرام) أو ٩٦ مليون وحدة <strong>[MU]</strong> (٩٦٠ ميكروجرامًا) من فيلجراستيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محلول نيفيستيم ١٢ مليون وحدة/٠.٢ مل المخصص للحقن/التسريب: تحتوي كل محقنة مسبقة التعبئة على ١٢ مليون وحدة (<strong>MU</strong>)، ١٢٠ ميكروجرامًا من فيلجراستيم في ٠.٢ مل (يعادل ٠.٦ ملجم/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محلول نيفيستيم ٣٠ مليون وحدة/٠.٥ مل المخصص للحقن/التسريب: تحتوي كل محقنة مسبقة التعبئة على ٣٠ مليون وحدة (<strong>MU</strong>)، ٣٠٠ ميكروجرام من فيلجراستيم في ٠.٥ مل (يعادل ٠.٦ ملجم/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محلول نيفيستيم ٤٨ مليون وحدة/٠.٥ مل المخصص للحقن/التسريب: تحتوي كل محقنة مسبقة التعبئة على ٤٨ مليون وحدة (<strong>MU</strong>)، ٤٨٠ ميكروجرامًا من فيلجراستيم في ٠.٥ مل (يعادل ٠.٩٦ ملجم/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي حمض الخليك (الجليدي)، وهيدروكسيد الصوديوم، وسوربيتول <strong>E</strong>٤٢٠، وبوليسوربات ٨٠، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نيفيستيم هو محلول صاف عديم اللون مخصص للحقن/التسريب في محقنة مسبقة التعبئة زجاجية ذات إبرة حقن (من الفولاذ المقاوم للصدأ) مع واقي إبرة. يحتوي غطاء الإبرة على الإيبوكسيبرين، وهو مشتق من المطاط الطبيعي الذي قد يتلامس مع الإبرة.</p><p dir="RTL">يوجد في كل عبوة محقنة واحدة أو ٥ أو ٨ أو ١٠ محاقن. قد لا يتم طرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Pfizer Europe MA EEIG, Belgium، بلجيكا</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة</strong></p><p dir="RTL">Hospira Zagreb d.o.o., Croatia، كرواتيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر/كانون الأول 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nivestim 12 MU/0.2 ml solution for injection/infusion
Nivestim 30 MU/0.5 ml solution for injection/infusion
Nivestim 48 MU/0.5 ml solution for injection/infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nivestim 120 mcg / 0.2 ml solution for injection/infusion, 
Each ml of solution for injection or infusion contains 60 million units [MU] (600 micrograms [mcg]) of filgrastim*.

Each pre-filled syringe contains 12 million units (MU) (120 micrograms [mcg]) of filgrastim in 0.2 ml (0.6 mg/ml).

Nivestim 300 mcg / 0.5 ml solution for injection/infusion
Each ml of solution for injection or infusion contains 60 million units (MU) (600 micrograms) of filgrastim*.

Each pre-filled syringe contains 30 million units (MU) (300 micrograms) of filgrastim in 0.5 ml (0.6 mg/ml).

Nivestim 480 mcg / 0.5 ml solution for injection/infusion
Each ml of solution for injection or infusion contains 96 million units (MU) (960 micrograms) of filgrastim*.

Each pre-filled syringe contains 48 million units (MU) (480 micrograms) of filgrastim in 0.5 ml (0.96 mg/ml).

*recombinant methionyl granulocyte colony-stimulating factor G CSF produced in Escherichia coli (BL21) by recombinant DNA technology.

Excipient with known effect
Each ml of solution contains 50 mg of sorbitol (E420) (see section 4.4).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion (injection/infusion).

Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.</p><p>&nbsp;</p><p>The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.</p><p>&nbsp;</p><p>Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).</p><p>&nbsp;</p><p>In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of &le; 0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.</p><p>&nbsp;</p><p>Filgrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0&nbsp;&times;&nbsp;10<sup>9</sup>/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim therapy should only be given in collaboration with an oncology centre which has experience in G‑CSF treatment and haematology and has the necessary diagnostic facilities. The mobilisation and apheresis procedures should be performed in collaboration with an oncology‑haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.</p><p><em>&nbsp;</em></p><p><u>Established cytotoxic chemotherapy</u></p><p><u>&nbsp;</u></p><p><em>Posology</em></p><p>&nbsp;</p><p>The recommended dose of filgrastim is 0.5&nbsp;MU (5&nbsp;mcg)/kg/day. The first dose of filgrastim should be administered at least 24&nbsp;hours after cytotoxic chemotherapy. In randomised clinical trials, a subcutaneous dose of 230&nbsp;mcg/m<sup>2</sup>/day (4.0 to 8.4&nbsp;mcg/kg/day) was used.</p><p>&nbsp;</p><p>Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemia, it is expected that the duration of treatment required to fulfil these criteria will be up to 14&nbsp;days. Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38&nbsp;days) depending on the type, dose and schedule of cytotoxic chemotherapy used.</p><p>&nbsp;</p><p>In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1&nbsp;to&nbsp;2&nbsp;days after initiation of filgrastim therapy. However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range. Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution given over 30&nbsp;minutes (see section 6.6)<em>.</em> The subcutaneous route is preferred in most cases. There is some evidence from a study of single dose administration that intravenous dosing may shorten the duration of effect. The clinical relevance of this finding to multiple dose administration is not clear. The choice of route should depend on the individual clinical circumstance.</p><p>&nbsp;</p><p><u>In patients treated with myeloablative therapy followed by bone marrow transplantation</u></p><p><em>&nbsp;</em></p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>The recommended starting dose of filgrastim is 1.0&nbsp;MU (10&nbsp;mcg)/kg/day. The first dose of filgrastim should be administered at least 24&nbsp;hours following cytotoxic chemotherapy and at least 24&nbsp;hours after bone marrow infusion.</p><p>&nbsp;</p><p>Once the neutrophil nadir has been passed, the daily dose of filgrastim should be titrated against the neutrophil response as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Neutrophil count</strong></p></td><td style="vertical-align:top"><p><strong>Filgrastim dose adjustment</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.0&nbsp;&times;&nbsp;10<sup>9</sup>/L for 3 consecutive days</p></td><td style="vertical-align:top"><p>Reduce to 0.5&nbsp;MU (5&nbsp;mcg)/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Then, if ANC remains &gt; 1.0 &times; 10<sup>9</sup>/L for 3 more consecutive days</p></td><td style="vertical-align:top"><p>Discontinue filgrastim</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>If the ANC decreases to &lt; 1.0 &times; 10<sup>9</sup>/L during the treatment period the dose of filgrastim should be re‑escalated according to the above steps.</p></td></tr></tbody></table><p>ANC = absolute neutrophil count</p><p><em><u>&nbsp;</u></em></p><p><em>Method of administration</em></p><p><em><u>&nbsp;</u></em></p><p>Filgrastim may be given as a 30&nbsp;minute or 24&nbsp;hour intravenous infusion or given by continuous 24&nbsp;hour subcutaneous infusion. Filgrastim should be diluted in 20&nbsp;ml of 5% glucose solution (see section 6.6).</p><p><em><u>&nbsp;</u></em></p><p><u>For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation</u></p><p><u>&nbsp;</u></p><p><em>Posology</em></p><p>&nbsp;</p><p>The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0&nbsp;MU (10&nbsp;mcg)/kg/day for 5 to 7&nbsp;consecutive days. Timing of leukapheresis: one or two leukapheresis on days&nbsp;5 and 6 are often sufficient. In other circumstances, additional leukapheresis may be necessary. Filgrastim dosing should be maintained until the last leukapheresis.</p><p>&nbsp;</p><p>The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5&nbsp;MU (5&nbsp;mcg)/kg/day from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Leukapheresis should be performed during the period when the ANC rises from &lt;&nbsp;0.5&nbsp;&times;&nbsp;10<sup>9</sup>/L to &gt;&nbsp;5.0&nbsp;&times;&nbsp;10<sup>9</sup>/L. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient. In other circumstances, additional leukapheresis is recommended.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Filgrastim for PBPC mobilisation when used alone:</p><p>&nbsp;</p><p>Filgrastim may be given as a 24&nbsp;hour subcutaneous continuous infusion or subcutaneous injection. For infusions filgrastim should be diluted in 20&nbsp;ml of 5% glucose solution (see section 6.6).</p><p>&nbsp;</p><p>Filgrastim for PBPC mobilisation after myelosuppressive chemotherapy:</p><p>&nbsp;</p><p>Filgrastim should be given by subcutaneous injection.</p><p>&nbsp;</p><p><u>For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation</u></p><p><u>&nbsp;</u></p><p><em>Posology</em></p><p><u>&nbsp;</u></p><p>For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MU (10&nbsp;mcg)/kg/day for 4 to 5 consecutive days. Leukapheresis should be started at day&nbsp;5 and continued until day&nbsp;6 if needed in order to collect 4&nbsp;&times;&nbsp;10<sup>6</sup> CD34<sup>+</sup> cells/kg recipient bodyweight.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>&nbsp;</p><p>Filgrastim should be given by subcutaneous injection.</p><p>&nbsp;</p><p><u>In patients with severe chronic neutropenia (SCN)</u></p><p><u>&nbsp;</u></p><p><em>Posology</em></p><p>&nbsp;</p><p>Congenital neutropenia: The recommended starting dose is 1.2&nbsp;MU&nbsp;(12&nbsp;mcg)/kg/day as a single dose or in divided doses.</p><p>&nbsp;</p><p>Idiopathic or cyclic neutropenia: The recommended starting dose is 0.5&nbsp;MU&nbsp;(5&nbsp;mcg)/kg/day as a single dose or in divided doses.</p><p>&nbsp;</p><p>Dose adjustment: Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5&nbsp;&times;&nbsp;10<sup>9</sup>/L. When the response has been obtained the minimal effective dose to maintain this level should be established. Long term daily administration is required to maintain an adequate neutrophil count. After one to two weeks of therapy, the initial dose may be doubled or halved depending upon the patient&#39;s response. Subsequently the dose may be individually adjusted every 1 to 2&nbsp;weeks to maintain the average neutrophil count between 1.5&nbsp;&times;&nbsp;10<sup>9</sup>/L and 10&nbsp;&times;&nbsp;10<sup>9</sup>/L. A faster schedule of dose escalation may be considered in patients presenting with severe infections. In clinical trials, 97% of patients who responded had a complete response at doses &le;&nbsp;24&nbsp;mcg/kg/day. The long‑term safety of filgrastim administration above 24&nbsp;mcg/kg/day in patients with SCN has not been established.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>Congenital, idiopathic or cyclic neutropenia: Filgrastim should be given by subcutaneous injection.</p><p>&nbsp;</p><p><u>In patients with HIV infection</u></p><p><em>&nbsp;</em></p><p><em>Posology</em></p><p><em>&nbsp;</em></p><p>For reversal of neutropenia:</p><p>&nbsp;</p><p>The recommended starting dose of filgrastim is 0.1&nbsp;MU (1&nbsp;mcg)/kg/day with titration up to a maximum of 0.4&nbsp;MU (4&nbsp;mcg)/kg/day until a normal neutrophil count is reached and can be maintained (ANC &gt;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>9</sup>/L). In clinical studies, &gt;&nbsp;90% of patients responded at these doses, achieving reversal of neutropenia in a median of 2&nbsp;days.</p><p>&nbsp;</p><p>In a small number of patients (&lt;&nbsp;10%), doses up to 1.0&nbsp;MU (10&nbsp;mcg)/kg/day were required to achieve reversal of neutropenia.</p><p>&nbsp;</p><p>For maintaining normal neutrophil counts:</p><p>&nbsp;</p><p>When reversal of neutropenia has been achieved, the minimal effective dose to maintain a normal neutrophil count should be established. Initial dose adjustment to alternate day dosing with 30&nbsp;MU (300&nbsp;mcg)/day is recommended. Further dose adjustment may be necessary, as determined by the patient&#39;s ANC, to maintain the neutrophil count at &gt;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>9</sup>/L. In clinical studies, dosing with 30&nbsp;MU (300&nbsp;mcg)/day on 1 to 7&nbsp;days per week was required to maintain the ANC &gt;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>9</sup>/L, with the median dose frequency being 3&nbsp;days per week. Long term administration may be required to maintain the ANC &gt;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>9</sup>/L.</p><p><strong>&nbsp;</strong></p><p><em>Method of administration</em></p><p><strong>&nbsp;</strong></p><p>Reversal of neutropenia or maintaining normal neutrophil counts: filgrastim should be given by subcutaneous injection.</p><p><strong>&nbsp;</strong></p><p><u>Elderly</u></p><p><em>&nbsp;</em></p><p>Clinical trials with filgrastim have included a small number of elderly patients but special studies have not been performed in this group and therefore specific dosage recommendations cannot be made.</p><p>&nbsp;</p><p><u>Renal or hepatic impairment</u></p><p><u>&nbsp;</u></p><p>Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals. Dose adjustment is not required in these circumstances.</p><p>&nbsp;</p><p><u>Paediatric use in the SCN and cancer settings</u></p><p>&nbsp;</p><p>Sixty-five percent of the patients studied in the SCN trial program were under 18&nbsp;years of age. The efficacy of treatment was clear for this age group, which included most patients with congenital neutropenia. There were no differences in the safety profiles for paediatric patients treated for SCN.</p><p>&nbsp;</p><p>Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.</p><p>&nbsp;</p><p>The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Special warnings and precautions across indications</u></p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p>&nbsp;</p><p>Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment have been reported in patients treated with filgrastim. Permanently discontinue filgrastim in patients with clinically significant hypersensitivity. Do not administer filgrastim to patients with a history of hypersensitivity to filgrastim or pegfilgrastim.</p><p>&nbsp;</p><p><em>Pulmonary adverse effects</em></p><p><em>&nbsp;</em></p><p>Pulmonary adverse effects, in particular interstitial lung disease, have been reported after G-CSF administration. Patients with a recent history of lung infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome (ARDS). Filgrastim should be discontinued and appropriate treatment given.</p><p>&nbsp;</p><p><em>Glomerulonephritis</em></p><p>&nbsp;</p><p>Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. Generally, events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim. Urinalysis monitoring is recommended.</p><p>&nbsp;</p><p><em>Capillary leak syndrome</em></p><p>&nbsp;</p><p>Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported after granulocyte-colony-stimulating factor administration, and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care (see section 4.8).</p><p>&nbsp;</p><p><em>Splenomegaly and splenic rupture</em></p><p>&nbsp;</p><p>Generally asymptomatic cases of splenomegaly and cases of splenic rupture have been reported in patients and normal donors following administration of filgrastim. Some cases of splenic rupture were fatal. Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal or shoulder tip pain. Dose reductions of filgrastim have been noted to slow or stop the progression of splenic enlargement in patients with severe chronic neutropenia, and in 3% of patients a splenectomy was required.</p><p>&nbsp;</p><p><em>Malignant cell growth</em></p><p><u>&nbsp;</u></p><p>Granulocyte colony-stimulating factor can promote growth of myeloid cells <em>in vitro</em> and similar effects may be seen on some non-myeloid cells <em>in vitro</em>.</p><p>&nbsp;</p><p><em>Myelodysplastic syndrome or Chronic myeloid leukaemia</em></p><p>&nbsp;</p><p>The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome, or chronic myelogenous leukaemia have not been established. Filgrastim is not indicated for use in these conditions. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from acute myeloid leukaemia.</p><p>&nbsp;</p><p><em>Acute myeloid leukaemia</em></p><p>&nbsp;</p><p>In view of limited safety and efficacy data in patients with secondary AML, filgrastim should be administered with caution. The safety and efficacy of filgrastim administration in <em>de novo</em> AML patients aged &lt;&nbsp;55&nbsp;years with good cytogenetics (t(8;21), t(15;17), and inv(16)) have not been established.</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p>&nbsp;</p><p>Thrombocytopenia has been reported in patients receiving filgrastim. Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy. Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count &lt;&nbsp;100&nbsp;&times;&nbsp;10<sup>9</sup>/L).<em> </em></p><p>&nbsp;</p><p><em>Leucocytosis</em></p><p>&nbsp;</p><p>White blood cell counts of 100 &times; 10<sup>9</sup>/L or greater have been observed in less than 5% of cancer patients receiving filgrastim at doses above 0.3&nbsp;MU/kg/day (3&nbsp;mcg/kg/day). No undesirable effects directly attributable to this degree of leucocytosis have been reported. However, in view of the potential risks associated with severe leucocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy. If leucocyte counts exceed 50&nbsp;&times;&nbsp;10<sup>9</sup>/L after the expected nadir, filgrastim should be discontinued immediately. When administered for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leucocyte counts rise to &gt;&nbsp;70&nbsp;&times;&nbsp;10<sup>9</sup>/L.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p><em>&nbsp;</em></p><p>As with all therapeutic proteins, there is a potential for immunogenicity. Rate of generation of antibodies against filgrastim is generally low. Binding antibodies do occur as expected with all biologics; however, they have not been associated with neutralising activity at present.</p><p>&nbsp;</p><p><em>Aortitis</em></p><p>&nbsp;</p><p>Aortitis has been reported after G‑CSF administration in healthy subjects and in cancer patients. The symptoms experienced included fever, abdominal pain, malaise, back pain and increased inflammatory markers (e.g. C‑reactive protein and white blood cell count). In most cases, aortitis was diagnosed by CT scan and generally resolved after withdrawal of G‑CSF (see section 4.8).</p><p>&nbsp;</p><p><u>Special warnings and precautions associated with co-morbidities</u></p><p>&nbsp;</p><p><em>Special precautions in sickle cell trait and sickle cell disease</em></p><p><em>&nbsp;</em></p><p>Sickle cell crises, in some cases fatal, have been reported with the use of filgrastim in patients with sickle cell trait or sickle cell disease. Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease.</p><p>&nbsp;</p><p><em>Osteoporosis</em></p><p><em>&nbsp;</em></p><p>Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.</p><p>&nbsp;</p><p><u>Special precautions in cancer patients</u></p><p>&nbsp;</p><p>Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established dosage regimens.</p><p>&nbsp;</p><p><em>Risks associated with increased doses of chemotherapy</em></p><p>&nbsp;</p><p>Special caution should be used when treating patients with high dose chemotherapy, because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic, and dermatologic effects (please refer to the prescribing information of the specific chemotherapy agents used).</p><p>&nbsp;</p><p><em>Effect of chemotherapy on erythrocytes and thrombocytes</em></p><p>&nbsp;</p><p>Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy. Because of the potential of receiving higher doses of chemotherapy (e.g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.</p><p>&nbsp;</p><p>The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.</p><p>&nbsp;</p><p><em>Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients</em></p><p>&nbsp;</p><p>In the post-marketing observational study setting, myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been associated with the use of pegfilgrastim, an alternative G-CSF medicine, in conjunction with chemotherapy and/or radiotherapy in breast and lung cancer patients. A similar association between filgrastim and MDS/AML has not been observed. Nonetheless, patients with breast cancer and patients with lung cancer should be monitored for signs and symptoms of MDS/AML.</p><p>&nbsp;</p><p><em>Other special precautions </em></p><p>&nbsp;</p><p>The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied. Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts. Therefore, in patients with reduced precursors neutrophil response may be diminished (such as those treated with extensive radiotherapy or chemotherapy, or those with bone marrow infiltration by tumour).</p><p>&nbsp;</p><p>Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by transplantation.</p><p>&nbsp;</p><p>There have been reports of graft versus host disease (GvHD) and fatalities in patients receiving G‑CSF after allogeneic bone marrow transplantation (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p>Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient abnormal bone scans. This should be considered when interpreting bone‑imaging results.</p><p>&nbsp;</p><p><u>Special precautions in patients undergoing PBPC mobilisation</u></p><p>&nbsp;</p><p><em>Mobilisation</em></p><p>&nbsp;</p><p>There are no prospectively randomised comparisons of the two recommended mobilisation methods (filgrastim alone, or in combination with myelosuppressive chemotherapy) within the same patient population. The degree of variation between individual patients and between laboratory assays of CD34<sup>+</sup> cells mean that direct comparison between different studies is difficult. It is therefore difficult to recommend an optimum method. The choice of mobilisation method should be considered in relation to the overall objectives of treatment for an individual patient.</p><p>&nbsp;</p><p><em>Prior exposure to cytotoxic agents</em></p><p>&nbsp;</p><p>Patients who have undergone very extensive prior myelosuppressive therapy may not show sufficient mobilisation of PBPC to achieve the recommended minimum yield (&ge;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>6 </sup>CD34<sup>+</sup>&nbsp;cells/kg) or acceleration of platelet recovery, to the same degree.</p><p>&nbsp;</p><p>Some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool, and may adversely affect progenitor mobilisation. Agents such as melphalan, carmustine (BCNU), and carboplatin, when administered over prolonged periods prior to attempts at progenitor mobilisation may reduce progenitor yield. However, the administration of melphalan, carboplatin or BCNU together with filgrastim has been shown to be effective for progenitor mobilisation. When a PBPC transplantation is envisaged it is advisable to plan the stem cell mobilisation procedure early in the treatment course of the patient. Particular attention should be paid to the number of progenitors mobilised in such patients before the administration of high-dose chemotherapy. If yields are inadequate, as measured by the criteria above, alternative forms of treatment, not requiring progenitor support should be considered.</p><p>&nbsp;</p><p><em>Assessment of progenitor cell yields</em></p><p>&nbsp;</p><p>In assessing the number of progenitor cells harvested in patients treated with filgrastim, particular attention should be paid to the method of quantitation. The results of flow cytometric analysis of CD34<sup>+</sup> cell numbers vary depending on the precise methodology used and recommendations of numbers based on studies in other laboratories need to be interpreted with caution.</p><p>&nbsp;</p><p>Statistical analysis of the relationship between the number of CD34<sup>+</sup> cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship.</p><p>&nbsp;</p><p>The recommendation of a minimum yields of &ge;&nbsp;2.0&nbsp;&times;&nbsp;10<sup>6 </sup>CD34<sup>+</sup> cells/kg is based on published experience resulting in adequate haematologic reconstitution. Yields in excess of this appear to correlate with more rapid recovery, those below with slower recovery.</p><p>&nbsp;</p><p><u>Special precautions in normal donors undergoing PBPC mobilisation</u></p><p>&nbsp;</p><p>Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.</p><p>&nbsp;</p><p>PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.</p><p>&nbsp;</p><p>The safety and efficacy of filgrastim have not been assessed in normal donors &lt;&nbsp;16&nbsp;years or &gt;&nbsp;60&nbsp;years.</p><p>&nbsp;</p><p>Transient thrombocytopenia (platelets &lt;&nbsp;100&nbsp;&times;&nbsp;10<sup>9</sup>/L) following filgrastim administration and leukapheresis was observed in 35% of subjects studied. Among these, two cases of platelets &lt;&nbsp;50&nbsp;&times;&nbsp;10<sup>9</sup>/L were reported and attributed to the leukapheresis procedure.</p><p>&nbsp;</p><p>If more than one leukapheresis is required, particular attention should be paid to donors with platelets &lt;&nbsp;100&nbsp;&times;&nbsp;10<sup>9</sup>/L prior to leukapheresis; in general apheresis should not be performed if platelets &lt;&nbsp;75&nbsp;&times;&nbsp;10<sup>9</sup>/L.</p><p>&nbsp;</p><p>Leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.</p><p>&nbsp;</p><p>Donors who receive G‑CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.</p><p>&nbsp;</p><p>Transient cytogenetic abnormalities have been observed in normal donors following G‑CSF use. The significance of these changes is unknown. Nevertheless, a risk of promotion of a malignant myeloid clone cannot be excluded. It is recommended that the apheresis centre perform a systematic record and tracking of the stem cell donors for at least 10&nbsp;years to ensure monitoring of long‑term safety.</p><p>&nbsp;</p><p><em>Special precautions in recipients of allogeneic PBPCs mobilised with filgrastim</em></p><p>&nbsp;</p><p>Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.</p><p>&nbsp;</p><p><u>Special precautions in SCN patients</u></p><p>&nbsp;</p><p>Filgrastim should not be administered to patients with severe congenital neutropenia who develop leukaemia or have evidence of leukaemic evolution.</p><p><em>&nbsp;</em></p><p><em>Blood cell counts</em></p><p>&nbsp;</p><p>Other blood cell changes occur, including anaemia and transient increases in myeloid progenitors, which require close monitoring of cell counts.</p><p>&nbsp;</p><p><em>Transformation to leukaemia or myelodysplastic syndrome</em></p><p>&nbsp;</p><p>Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia. Complete blood cell counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.</p><p>&nbsp;</p><p>There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim. This observation has only been made in patients with congenital neutropenia. MDS and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy. A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline were subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation. It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation. It is recommended to perform morphologic and cytogenetic bone marrow examinations in patients at regular intervals (approximately every 12&nbsp;months).</p><p>&nbsp;</p><p><em>Other special precautions </em></p><p>&nbsp;</p><p>Causes of transient neutropenia, such as viral infections should be excluded.</p><p>&nbsp;</p><p>Haematuria was common and proteinuria occurred in a small number of patients. Regular urinalysis should be performed to monitor these events.</p><p>&nbsp;</p><p>The safety and efficacy in neonates and patients with autoimmune neutropenia have not been established.</p><p>&nbsp;</p><p><u>Special precautions in patients with HIV infection</u></p><p>&nbsp;</p><p><em>Blood cell counts</em></p><p>&nbsp;</p><p>Absolute neutrophil count (ANC) should be monitored closely, especially during the first few weeks of filgrastim therapy. Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim. It is recommended that the ANC is measured daily for the first 2-3&nbsp;days of filgrastim administration. Thereafter, it is recommended that the ANC is measured at least twice per week for the first two weeks and subsequently once per week or once every other week during maintenance therapy. During intermittent dosing with 30&nbsp;MU (300&nbsp;mcg)/day of filgrastim, there can be wide fluctuations in the patient&#39;s ANC over time. In order to determine a patient&#39;s trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.</p><p>&nbsp;</p><p><em>Risk associated with increased doses of myelosuppressive medicinal products</em></p><p>&nbsp;</p><p>Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medications. As a result of the potential to receive higher doses or a greater number of these medications with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia. Regular monitoring of blood counts is recommended (see above).</p><p>&nbsp;</p><p><em>Infections and malignancies causing myelosuppression</em></p><p>&nbsp;</p><p>Neutropenia may be due to bone marrow infiltrating opportunistic infections such as <em>Mycobacterium avium</em> complex or malignancies such as lymphoma. In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition, in addition to administration of filgrastim for treatment of neutropenia. The effects of filgrastim on neutropenia due to bone marrow infiltrating infection or malignancy have not been well established.</p><p>&nbsp;</p><p><u>All patients</u></p><p>&nbsp;</p><p>Nivestim contains sorbitol (E420). Patients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly necessary.</p><p>&nbsp;</p><p>Babies and young children (below 2&nbsp;years of age) may not yet be diagnosed with hereditary fructose intolerance (HFI). Medicines (containing sorbitol/fructose) given intravenously may be life‑threatening and should be contraindicated in this population unless there is an overwhelming clinical need and no alternatives are available.</p><p>&nbsp;</p><p>A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 0.6&nbsp;mg/ml or 0.96&nbsp;mg/ml dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24&nbsp;hours before to 24&nbsp;hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-Fluorouracil indicates that the severity of neutropenia may be exacerbated.</p><p>&nbsp;</p><p>Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.</p><p>&nbsp;</p><p>Since lithium promotes the release of neutrophils, lithium is likely to potentiate the effect of filgrastim. Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data from the use of filgrastim in pregnant women. Studies in animals have shown reproductive toxicity. An increased incidence of embryo loss has been observed in rabbits at high multiples of the clinical exposure and in the presence of maternal toxicity (see section 5.3). There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated.</p><p>&nbsp;</p><p>Filgrastim is not recommended during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is unknown whether filgrastim/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p><em>&nbsp;</em></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Filgrastim did not affect reproductive performance or fertility in male or female rats (see section 5.3).</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nivestim may have a minor influence on the ability to drive and use machines. Dizziness may occur following the administration of filgrastim (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>&nbsp;</em></p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea. In clinical trials in cancer patients musculoskeletal pain was mild or moderate in 10%, and severe in 3% of patients.</p><p><em>&nbsp;</em></p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The data in the table below describe adverse reactions reported from clinical trials and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>(&ge;</strong><strong>&nbsp;</strong><strong>1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;</strong><strong>&nbsp;</strong><strong>1/100 to &lt;</strong><strong>&nbsp;</strong><strong>1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;</strong><strong>&nbsp;</strong><strong>1/1,000 to &lt;</strong><strong>&nbsp;</strong><strong>1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;</strong><strong>&nbsp;</strong><strong>1/10,000 to &lt;</strong><strong>&nbsp;</strong><strong>1/1,000)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Sepsis</p><p>Bronchitis</p><p>Upper respiratory tract infection</p><p>Urinary tract infection</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Anaemia<sup>e</sup></p></td><td style="vertical-align:top"><p>Splenomegaly<sup>a</sup></p><p>Haemoglobin decreased<sup>e</sup></p></td><td style="vertical-align:top"><p>Leucocytosis<sup>a</sup></p></td><td style="vertical-align:top"><p>Splenic rupture<sup>a</sup></p><p>Sickle cell anaemia with crisis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>Drug hypersensitivity<sup>a</sup></p><p>Graft versus host disease<sup>b</sup></p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Decreased appetite<sup>e</sup></p><p>Blood lactate dehydrogenase increased</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hyperuricaemia</p><p>Blood uric acid increased</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Blood glucose decreased</p><p>Pseudogout<sup>a </sup>(Chondrocalcinosis Pyrophosphate)</p><p>Fluid volume disturbances</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache<sup>a</sup></p></td><td style="vertical-align:top"><p>Dizziness</p><p>Hypoaesthesia</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hypertension</p><p>Hypotension</p></td><td style="vertical-align:top"><p>Veno-occlusive disease<sup>d</sup></p></td><td style="vertical-align:top"><p>Capillary leak syndrome<sup>a</sup></p><p>Aortitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Haemoptysis</p><p>Dyspnoea</p><p>Cough<sup>a</sup></p><p>Oropharyngeal pain<sup>a,e</sup></p><p>Epistaxis</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome<sup>a</sup></p><p>Respiratory failure<sup>a</sup></p><p>Pulmonary oedema<sup>a</sup></p><p>Pulmonary haemorrhage</p><p>Interstitial lung disease<sup>a</sup></p><p>Lung infiltration<sup>a</sup></p><p>Hypoxia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea<sup>a,e</sup></p><p>Vomiting<sup>a,e</sup></p><p>Nausea<sup>a</sup></p></td><td style="vertical-align:top"><p>Oral pain</p><p>Constipation<sup>e</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hepatomegaly</p><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p><p>Gamma-glutamyl transferase increased</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Alopecia<sup>a</sup></p></td><td style="vertical-align:top"><p>Rash<sup>a</sup></p><p>Erythema</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Rash maculo-papular</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Cutaneous vasculitis<sup>a</sup></p><p>Sweets syndrome(acute febrile neutrophilic dermatosis)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Musculoskeletal pain<sup>c</sup></p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Osteoporosis</p></td><td style="vertical-align:top"><p>Bone density decreased</p><p>Exacerbation of rheumatoid arthritis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Dysuria</p><p>Haematuria</p></td><td style="vertical-align:top"><p>Proteinuria</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Glomerulonephritis</p><p>Urine abnormality</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue<sup>a</sup></p><p>Mucosal inflammation<sup>a</sup></p><p>Pyrexia</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Chest pain<sup>a</sup></p><p>Pain<sup>a</sup></p><p>Asthenia<sup>a</sup></p><p>Malaise<sup>e</sup></p><p>Oedema peripheral<sup>e</sup></p></td><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transfusion reaction<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><sup>a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>See section c (Description of selected adverse reactions).</p><p><sup>b &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>There have been reports of GvHD and fatalities in patients after allogeneic bone marrow transplantation (see section c).</p><p><sup>c &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain.</p><p><sup>d &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or PBPC mobilisation.</p><p><sup>e</sup> &nbsp;&nbsp;&nbsp; Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy.</p><p><u>&nbsp;</u></p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Hypersensitivity</em></p><p>&nbsp;</p><p>Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post‑marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.</p><p>&nbsp;</p><p><em>Pulmonary adverse events</em></p><p>&nbsp;</p><p>In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Splenomegaly and splenic rupture</em></p><p>&nbsp;</p><p>Cases of splenomegaly and splenic rupture have been reported following administration of filgrastim. Some cases of splenic rupture were fatal (see section 4.4).</p><p>&nbsp;</p><p><em>Capillary leak syndrome</em></p><p>&nbsp;</p><p>Cases of capillary leak syndrome have been reported with granulocyte-colony-stimulating factor use. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).</p><p><u>&nbsp;</u></p><p><em>Cutaneous vasculitis</em></p><p><em>&nbsp;</em></p><p>Cutaneous vasculitis has been reported in patients treated with filgrastim. The mechanism of vasculitis in patients receiving filgrastim is unknown. During long-term use cutaneous vasculitis has been reported in 2% of SCN patients.</p><p>&nbsp;</p><p><em>Leucocytosis</em></p><p><em>&nbsp;</em></p><p>Leucocytosis (WBC &gt; 50 &times; 10<sup>9</sup>/L) was observed in 41% of normal donors and transient thrombocytopenia (platelets &lt; 100 &times; 10<sup>9</sup>/L) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).</p><p>&nbsp;</p><p><em>Sweets syndrome</em></p><p>&nbsp;</p><p>Cases of Sweets syndrome (acute febrile neutrophilic dermatosis) have been reported in patients treated with filgrastim.</p><p>&nbsp;</p><p><em>Pseudogout (chondrocalcinosis pyrophosphate</em>)</p><p>&nbsp;</p><p>Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim.</p><p><strong><u>&nbsp;</u></strong></p><p><em>GvHD</em></p><p><em>&nbsp;</em></p><p>There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see sections 4.4 and 5.1).</p><p><u>&nbsp;</u></p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u></p><p>&nbsp;</p><p>Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy suggesting no age-related differences in the pharmacokinetics of filgrastim. The only consistently reported adverse event was musculoskeletal pain&sbquo; which is no different from the experience in the adult population.</p><p>&nbsp;</p><p>There is insufficient data to further evaluate filgrastim use in paediatric subjects.</p><p>&nbsp;</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other special populations</u></p><p>&nbsp;</p><p><em>Geriatric use</em></p><p>&nbsp;</p><p>No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (&gt;&nbsp;18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients. There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.</p><p>&nbsp;</p><p><em>Paediatric SCN patients</em></p><p>&nbsp;</p><p>Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with filgrastim.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p>&nbsp;</p><p><strong>TO REPORT ANY SIDE EFFECTS:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effects of filgrastim overdosage have not been established.</p><p>&nbsp;</p><p>Discontinuation of filgrastim therapy usually results in a 50% decrease in circulating neutrophils within 1 to 2&nbsp;days, with a return to normal levels in 1 to 7&nbsp;days.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cytokines, ATC code: L03AA02</p><p>&nbsp;</p><p>Human G‑CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Nivestim containing r-metHuG‑CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within twenty four hours, with minor increases in monocytes. In some SCN patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dose dependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.</p><p>&nbsp;</p><p>Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia. Treatment with filgrastim significantly reduces the durations of febrile neutropenia, antibiotic use and hospitalisation after induction chemotherapy for acute myelogenous leukaemia or myeloablative therapy followed by bone marrow transplantation. The incidence of fever and documented infections were not reduced in either setting. The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.</p><p>&nbsp;</p><p>Use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into the peripheral blood. These autologous PBPCs may be harvested and infused after high dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation. Infusion of PBPC accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.</p><p>&nbsp;</p><p>Recipients of allogeneic PBPCs mobilised with filgrastim experienced significantly more rapid haematological recovery, leading to a significant decrease in time to unsupported platelet recovery when compared with allogeneic bone marrow transplantation.</p><p>&nbsp;</p><p>One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered. In a separate retrospective International study in patients with acute and chronic myelogenous leukaemias, no effect on the risk of GvHD, TRM and mortality was seen. A meta-analysis of allogeneic transplant studies, including the results of nine prospective randomised trials, 8 retrospective studies and 1 case-controlled study, did not detect an effect on the risks of acute GvHD, chronic GvHD or early treatment-related mortality.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="6" style="vertical-align:top"><p><strong>Relative Risk (95% CI) of GvHD and TRM</strong></p><p><strong>Following Treatment with GCSF after Bone Marrow Transplantation</strong></p></td></tr><tr><td><p><strong>Publication</strong></p></td><td><p><strong>Period of Study</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Acute Grade II - IV GvHD</strong></p></td><td><p><strong>Chronic GvHD</strong></p></td><td><p><strong>TRM</strong></p></td></tr></thead><tbody><tr><td><p>Meta-Analysis (2003)</p></td><td><p>1986 - 2001<sup>a</sup></p></td><td><p>1198</p></td><td><p>1.08</p><p>(0.87, 1.33)</p></td><td><p>1.02</p><p>(0.82, 1.26)</p></td><td><p>0.70</p><p>(0.38, 1.31)</p></td></tr><tr><td><p>European Retrospective Study (2004)</p></td><td><p>1992 - 2002<sup>b</sup></p></td><td><p>1789</p></td><td><p>1.33</p><p>(1.08, 1.64)</p></td><td><p>1.29</p><p>(1.02, 1.61)</p></td><td><p>1.73</p><p>(1.30, 2.32)</p></td></tr><tr><td><p>International Retrospective Study (2006)</p></td><td><p>1995 - 2000<sup>b</sup></p></td><td><p>2110</p></td><td><p>1.11</p><p>(0.86, 1.42)</p></td><td><p>1.10</p><p>(0.86, 1.39)</p></td><td><p>1.26</p><p>(0.95, 1.67)</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Analysis includes studies involving BM transplant during this period; some studies used GM-CSF.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Analysis includes patients receiving BM transplant during this period.</p><p>&nbsp;</p><p><u>Use of filgrastim for the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation</u></p><p>&nbsp;</p><p>In normal donors, a 10&nbsp;mcg/kg/day dose administered subcutaneously for 4 to 5&nbsp;consecutive days allows a collection of &ge;&nbsp;4 &times;&nbsp;10<sup>6</sup>&nbsp;CD34<sup>+</sup>&nbsp;cells/kg recipient body weight in the majority of the donors after two leukapheresis.</p><p><em>&nbsp;</em></p><p>Use of filgrastim in patients, children or adults, with SCN (severe congenital, cyclic, and idiopathic neutropenia) induces a sustained increase in absolute neutrophil counts in peripheral blood and a reduction of infection and related events.</p><p>&nbsp;</p><p>Use of filgrastim in patients with HIV infection maintains normal neutrophil counts to allow scheduled dosing of antiviral and/or other myelosuppressive medication. There is no evidence that patients with HIV infection treated with filgrastim show an increase in HIV replication.</p><p>&nbsp;</p><p>As with other haematopoietic growth factors, G‑CSF has shown <em>in vitro</em> stimulating properties on human endothelial cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A randomised, open-label, single-dose, comparator-controlled, two-way crossover study in 46 healthy volunteers showed that the pharmacokinetic profile of Nivestim was comparable to that of the reference product after subcutaneous and intravenous administration. Another randomised, double‑blind, multiple‑dose, comparator‑controlled, two‑way crossover study in 50&nbsp;healthy volunteers showed that the pharmacokinetic profile of Nivestim was comparable to that of the reference product after subcutaneous administration.</p><p>&nbsp;</p><p>Clearance of filgrastim has been shown to follow first-order pharmacokinetics after both subcutaneous and intravenous administration. The serum elimination half-life of filgrastim is approximately 3.5&nbsp;hours, with a clearance rate of approximately 0.6&nbsp;ml/min/kg. Continuous infusion with filgrastim over a period of up to 28&nbsp;days, in patients recovering from autologous bone-marrow transplantation, resulted in no evidence of drug accumulation and comparable elimination half-lives. There is a positive linear correlation between the dose and the serum concentration of filgrastim, whether administered intravenously or subcutaneously. Following subcutaneous administration of recommended doses, serum concentrations were maintained above 10&nbsp;ng/ml for 8 to 16&nbsp;hours. The volume of distribution in blood is approximately 150&nbsp;ml/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Filgrastim was studied in repeated dose toxicity studies up to 1 year in duration which revealed changes attributable to the expected pharmacological actions including increases in leucocytes, myeloid hyperplasia in bone marrow, extramedullary granulopoiesis and splenic enlargement. These changes all reversed after discontinuation of treatment.</p><p>&nbsp;</p><p>Effects of filgrastim on prenatal development have been studied in rats and rabbits. Intravenous (80&nbsp;mcg/kg/day) administration of filgrastim to rabbits during the period of organogenesis was maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and foetal weight were observed.</p><p>&nbsp;</p><p>Based on reported data for another filgrastim product similar to the originator, comparable findings plus increased foetal malformations were observed at 100 mcg/kg/day, a maternally toxic dose which corresponded to a systemic exposure of approximately 50-90 times the exposures observed in patients treated with the clinical dose of 5 mcg/kg/day. The no observed adverse effect level for embryo-foetal toxicity in this study was 10 mcg/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.</p><p>&nbsp;</p><p>In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 mcg/kg/day. Offspring of rats administered filgrastim during the peri-natal and lactation periods, exhibited a delay in external differentiation and growth retardation (&ge;&nbsp;20 mcg/kg/day) and slightly reduced survival rate (100&nbsp;mcg/kg/day).</p><p>&nbsp;</p><p>Filgrastim had no observed effect on the fertility of male or female rats.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acetic acid, glacial</p><p>Sodium hydroxide</p><p>Sorbitol (E420)</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nivestim should not be diluted with sodium chloride solutions.</p><p>&nbsp;</p><p>Diluted filgrastim may be adsorbed to glass and plastic materials unless it is diluted in 5% glucose solution (see section 6.6).</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre-filled syringe

30 months.

After dilution

Chemical and physical in-use stability of the diluted solution for infusion has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C to 8&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Accidental exposure to freezing temperatures for up to 24 hours does not affect the stability of Nivestim. The frozen pre-filled syringes can be thawed and then refrigerated for future use. If exposure has been greater than 24 hours or frozen more than once, then Nivestim should NOT be used.</p><p>&nbsp;</p><p>Within its shelf-life and for the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at room temperature (not above 25&deg;C) for one single period of up to 15 days. At the end of this period, the product should not be put back in the refrigerator and should be disposed of.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Nivestim 120 mcg/0.2&nbsp;ml solution for injection/infusion</u></p><p>Pre-filled syringe (type I glass), with injection needle (stainless steel) with a needle guard, containing 0.2&nbsp;ml solution for injection/infusion.</p><p>&nbsp;</p><p><u>Nivestim 300 mcg/0.5&nbsp;ml solution for injection/infusion</u></p><p>Pre-filled syringe (type I glass), with injection needle (stainless steel) with a needle guard, containing 0.5&nbsp;ml solution for injection/infusion.</p><p><u>&nbsp;</u></p><p><u>Nivestim 480 mcg/0.5&nbsp;ml solution for injection/infusion</u></p><p>Pre-filled syringe (type I glass), with injection needle (stainless steel) with a needle guard, containing 0.5&nbsp;ml solution for injection/infusion.</p><p>&nbsp;</p><p>Each pre‑filled syringe is affixed with a needle closed by a needle cover that contains epoxyprene, a derivative of natural rubber latex which may come into contact with the needle.</p><p>&nbsp;</p><p>Pack sizes of 1, 5, 8 or 10 pre-filled syringes.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of sight and reach of children.</p><p>&nbsp;</p><p>If required, Nivestim may be diluted in 5% glucose solution.</p><p>&nbsp;</p><p>Dilution to a final concentration less than 0.2&nbsp;MU (2&nbsp;mcg) per ml is not recommended at any time.</p><p>&nbsp;</p><p>The solution should be visually inspected prior to use. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>For patients treated with filgrastim diluted to concentrations below 1.5&nbsp;MU (15&nbsp;mcg) per ml, human serum albumin (HSA) should be added to a final concentration of 2 mg/ml.</p><p>&nbsp;</p><p>Example: In a final injection volume of 20&nbsp;ml, total doses of filgrastim less than 30&nbsp;MU (300&nbsp;mcg) should be given with 0.2&nbsp;ml of 20% human albumin solution Ph. Eur. added.</p><p>&nbsp;</p><p>Nivestim contains no preservative. In view of the possible risk of microbial contamination, Nivestim syringes are for single use only.</p><p>&nbsp;</p><p>When diluted in 5% glucose solution, filgrastim is compatible with glass and a variety of plastics including PVC, polyolefin (a co-polymer of polypropylene and polyethylene) and polypropylene.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer Europe MA EEIG, Belgium
 
MANUFACTURER
Hospira Zagreb d.o.o., Croatia


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>